Tanshinone IIA effects on ovarian cancer cell line

  • J Pharm Pharmacol. 2018 Oct;70(10):1369-1377. doi: 10.1111/jphp.12961.
Nan Li  1 ,  Liang Yang  2 ,  Baolian Zhang  3 ,  Suqin Chen  1
Affiliations
  • 1. Department of Gynecology, the Second Hospital of Hebei Medical University, Shijiazhuang, China.
  • 2. Department of Neurosurgery, the Second Hospital of Hebei Medical University, Shijiazhuang, China.
  • 3. Department of Obstetrics, the Second Hospital of Hebei Medical University, Shijiazhuang, China.
PMID: 29943422 DOI: 10.1111/jphp.12961
Abstract

Objectives: To explore the potential therapeutic effect of Tanshinone IIA against ovarian Cancer in vitro and elucidate the underlying molecular mechanism.

Methods: The cell survival upon Tanshinone IIA treatment was determined by the clonogenic assay. Cell Apoptosis was analysed by Annexin V/propidium iodide double staining. The cleaved Caspase-3/poly ADP-ribose polymerase and apoptosis-related factors were quantified by Western blotting. The relative expression of MicroRNAs (miRs) was determined by real-time polymerase chain reaction.

Key findings: Tanshinone IIA treatment induced significant Apoptosis in TOV-21G cells. Tanshinone suppressed Survivin expression while not affected Bax, Bcl-2 and Bcl-xL. We further predicted and experimentally confirmed overexpression of miR-205 in TOV-21G, which ectopic significantly inhibited Survivin and promoted cell Apoptosis. miR-205-specific antagonist completely abrogated the cell suppressive effect of Tanshinone IIA.

Conclusions: Our data suggested that Tanshinone IIA induced cell Apoptosis in ovarian carcinoma TOV-21G cells via direct upregulation of miR-205. Our study highlighted the potential therapeutic application of Tanshinone IIA against ovarian malignancy.

Keywords
Tanshinone IIA; microRNA-205; ovarian carcinoma; survivin.
Products